Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombitek
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim Animal Health
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Subcutaneous, Intramuscular, Intranasal, Oral
01
Overview
Recombitek is a comprehensive line of veterinary vaccines developed by Boehringer Ingelheim for the prevention of various infectious diseases in dogs. The product line utilizes diverse vaccine technologies, most notably a recombinant canarypox vector platform that expresses specific viral glycoproteins (such as those from canine distemper virus or Borrelia burgdorferi) to induce a targeted immune response without the risk of viral shedding or reversion to virulence. Other formulations within the Recombitek family include modified live viruses, inactivated bacterins, and purified recombinant proteins. These vaccines are indicated for the protection of healthy dogs against pathogens including canine distemper virus, parvovirus, adenovirus types 1 and 2, parainfluenza, coronavirus, *Leptospira* serovars, *Bordetella bronchiseptica*, and Lyme disease.
- Brand names
- Recombitek
02
Targets
Bordetella bronchiseptica antigensOspA (Outer surface protein A)CAdV-2 (Canine adenovirus type 2)CDV (Canine distemper virus)Canine parainfluenza virus antigensLeptospira interrogans serovar antigens
Beyond the preview
Go deeper on Recombitek.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Recombitek.